Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of ...

Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration ...

A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

One of the most highly anticipated FDA decisions this month is for Alnylam Pharmaceuticals, which is seeking to expand the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Shares in US biotech Alnylam have soared after a late-stage study of its RNA interference drug patisaran met its primary endpoint. The results are a landmark for Alnylam which has stuck doggedly ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Northwestern Medicine scientists have uncovered new insights into how neurofilaments act like Velcro in neurodegenerative ...

Arrowhead (ARWR) announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference ...

Initial validation using orthotopic models: SIL204 administered subcutaneously (systemically) showed significant efficacy in ...

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi), a cutting-edge technology that targets RNA to silence genes involved in diseases. It has a strong catalog of approved products and a ...